Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
Reslizumab
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Llega reslizumab, terapia adicional reduce exacerbaciones asma grave
NICE changes mind and backs new drug for severe asthma | Nursing Times
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Reslizumab Overview - Creative Biolabs
Older Patients with Asthma Do Well with Reslizumab | RT
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
Reslizumab (Sch 55700) | IL-5 Antagonist mAb | MedChemExpress
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
Israeli Pharma gets FDA Approval for Asthma Antibody
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
Medication Detail
Help eligible, commercially insured patients save on out-of-pocket costs for CINQAIR*
Australian Public Assessment Report Reslizumab
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Dosing and Administration
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Reslizumab | New Drug Approvals
CINQAIR® (reslizumab) Injection – About Asthma Control
